Specialist Microscopy and AI Analysis Can Improve Lung Cancer Testing
“Research shows fluorescence lifetime imaging microscopy (FLIM) combined with a form of artificial intelligence (AI) known as deep learning can predict if a person has lung cancer-related EGFR mutations with no need for genetic testing or tissue staining.”
Kelun’s Merck & Co.-partnered ADC scores late-stage win in front-line PD-L1-negative NSCLC
“Top-line results showed the trial met its primary endpoint of blinded independent central review (BICR)-assessed progression-free survival (PFS) at a pre-specified interim analysis, with the sac-TMT plus Keytruda regimen demonstrating a statistically significant and clinically meaningful improvement over Keytruda plus chemotherapy, alongside a positive trend on overall survival.”
Ageing stress signalling: metastatic plasticity and metabolic vulnerability in lung cancer
“Ageing and cancer share several fundamental features, including proteostasis imbalance, epigenetic drift, mitochondrial dysfunction, and altered nutrient sensing. However, how these changes are integrated into tumour-intrinsic signalling networks is still not fully understood. This issue is particularly relevant in lung cancer, where most patients are elderly, while experimental models are typically based on young animals. Given that metastasis accounts for the majority of cancer-related deaths, identifying signalling pathways that connect ageing to metastatic progression remains an important challenge.”
Molecular models show promise for predicting lung cancer recurrence
“Molecular biomarkers such as gene expression profiles and DNA methylation markers can predict recurrence and survival in early-stage non-small cell lung cancer (NSCLC) with moderate to good accuracy, but most of the models built around them have never been tested outside the patient population where they were developed, according to a systematic review and meta-analysis published in Thoracic Cancer.”
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer
Post Hoc Analysis of the Neotorch Randomized Clinical Trial
“Findings: Among the surgical patients in this phase 3 randomized clinical trial, preoperative toripalimab plus chemotherapy showed significantly improved survival through effective tumor downstaging without new safety signals.”
UF researchers discover first-of-its-kind compound to target lung cancer cells
“JUPITER, Fla. — Inside cells, a large family of proteins known as heat shock proteins function like attentive mother hens. They shepherd less sophisticated proteins across cell membranes and help proteins assume the shape they need to function correctly.”
Tiny molecules, big possibilities: Researchers explore a new way to slow lung cancer
“Cancer develops when the body’s systems for controlling cell growth break down, allowing cells to multiply unchecked. Texas A&M researchers have identified two naturally occurring molecules that appear to help restore those controls, offering a potential new strategy for slowing the progression of lung cancer.”
Handling missing data: AI approach for survival prediction in lung cancer despite missing data
“Optimal cancer prognostication combines multimodal data including biopsy results, CT scan, patient characteristics, and clinical trajectory thus far. However, many patients do not have all modalities of data available, so requiring physicians to have all patient data modalities to use an AI prediction algorithm limits the tool’s clinical utility. To increase the clinical potential of these AI algorithms, Ruffini et al. developed a “missing data aware” survival prediction approach that is able to handle inputs with missing data for risk stratification in non-small cell lung cancer patients.”
Fibroblast-specific ablation of MHC-I antigen presentation via the IGF2 axis cripples CD8+ T cell surveillance in lung cancer
“How cancer-associated fibroblasts (CAFs) dictate CD8+ T cell dysfunction during lung cancer remains unclear. Through single-cell analysis of 84 human NSCLC samples, we identified insulin-like growth factor 2 (IGF2) as a key immunosuppressive factor in a specific CAF subset.”
Wildfire Smoke and Cancer Risk: What Patients Should Know
“Key Takeaways: Wildfire PM2.5 differs from routine air pollution by composition, with higher elemental and organic carbon fractions that increase free-radical burden and intensify oxidative stress–mediated lung inflammation. Carcinogenic constituents include particulate matter and polycyclic aromatic hydrocarbons, despite wildfire smoke not being formally classified as an IARC Group 1 carcinogen.”
Durvalumab With Radiation Shows Promise in Chemotherapy-Ineligible Locally Advanced NSCLC
“A phase II study published in the Journal of Clinical Oncology evaluated a chemotherapy-free approach for patients with inoperable locally advanced non-small cell lung cancer who were not eligible for concurrent chemoradiotherapy. The study, known as DART, investigated durvalumab given concurrently with definitive radiation therapy and continued as consolidation treatment in patients considered unsuitable for standard concurrent platinum-based chemoradiotherapy because of age, comorbidities, or frailty.”
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
“Early-onset cancers, defined as cancers diagnosed in individuals younger than 50 years, have emerged as a growing public health concern worldwide, with incidence rates increasing across multiple tumor types despite advances in screening and prevention.”
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
“Key Takeaways: Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, versus 18% and 3% on atezolizumab alone. Overall survival numerically worsened with consolidative thoracic radiotherapy (median 6.7 vs 13.4 months; 1-year OS 30% vs 57%), despite no PFS improvement.”
